SCHEMBL7934104

SCHEMBL7934104

Nc1ncccc1NCc1cc(NC(=O)c2oc3ccc(Br)cc3c2N)ccn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.47
NPC1 O15118 5/20 0.47
MAPT P10636 5/20 0.41
ADORA2A P29274 1/20 0.41
CASP1 P29466 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
KDM4E B2RXH2 4/20 0.41
TP53 P04637 1/20 0.41
HSD17B10 Q99714 1/20 0.41
BACE1 P56817 6/20 0.40
L3MBTL1 Q9Y468 1/20 0.38
PRKCI P41743 1/20 0.38
POLB P06746 1/20 0.37
KMT2A Q03164 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
USP2 O75604 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
NFKB1 P19838 1/20 0.37
HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7945393 0.92 RAB9A (0.58) RAB9ANPC1MAPTSMN1; SMN2KDM4E
SCHEMBL7945232 0.88 BACE1 (0.53) RAB9ANPC1MAPTADORA2ACASP1
SCHEMBL7934111 0.85 RAB9A (0.44) RAB9ANPC1MAPTADORA2ACASP1
SCHEMBL7946790 0.84 RAB9A (0.55) RAB9ANPC1MAPTSMN1; SMN2KDM4E
SCHEMBL7935759 0.83 RAB9A (0.51) RAB9ANPC1MAPTSMN1; SMN2KDM4E
SCHEMBL7945003 0.83 RAB9A (0.56) RAB9ANPC1MAPTSMN1; SMN2KDM4E
SCHEMBL7943409 0.82 RAB9A (0.45) RAB9ANPC1MAPTSMN1; SMN2KDM4E
SCHEMBL7944977 0.82 RXFP1 (0.50) RAB9ANPC1MAPTSMN1; SMN2HSD17B10
SCHEMBL7946785 0.82 RAB9A (0.50) RAB9ANPC1MAPTSMN1; SMN2KDM4E
SCHEMBL7941381 0.81 BACE1 (0.52) BACE1PRKCI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-09-29 US disclosed
EP-2360155-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY Shionogi & Co., Ltd. (JP) 2011-08-24 EP disclosed
WO-2010047372-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY 塩野義製薬株式会社 (JP) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY BACE1, APP, BACE2 RAB9A 1287/4885NPC1 431/4885MAPT 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.